The FDA has set a Feb. 21 target decision on the Bysanti NDA. ・Vanda submitted the NDA in March 2025 for Bysanti to treat acute bipolar I disorder and schizophrenia. ・In May, the FDA said the ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2025 Earnings Call Transcript February 11, 2026 Vanda Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-2.39 EPS, expectations were ...

WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2025 on Wednesday, February 11, ...

Under the collaborative framework announced on October 1, 2025, the U.S. Food and Drug Administration (FDA) is conducting an expedited re-review of the partial clinical hold that currently restricts ...

WASHINGTON, Dec. 11, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, ...

Vanda reported strong phase 2 results for a candidate that could be used with GLP-1 drugs. However, this medicine's potential target market appears small and may shrink further. Even with some ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The cost of the approved drug ...

Our fourth quarter and full year 2025 results were released this afternoon and are available on the SEC’s EDGAR system and on our website, Joining me on today’s call is Mihael H. Polymeropoulos, our ...

Separately, review of the NDA for tradipitant for the prevention of vomiting induced by motion continues according to schedule, with an unchanged PDUFA target action date of December 30, 2025. The FDA ...